Musculoskeletal Tumor Center

Lars M. Wagner, MD

Appointment

Associate Professor of Clinical Pediatrics, University of Cincinnati College of Medicine

Email

lars.wagner@cchmc.org

Phone

513-636-4266

Fax

513-636-3549

Credentials

MD: University of Kentucky, Lexington, KY 1991.

Residency: Pediatrics, University of Tennessee, Memphis, TN.

Fellowship: Pediatric Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN.

Certification: Pediatrics, 1994.

Certification: Pediatric Hematology/Oncology, 2004.

Awards and Honors

Phi Beta Kappa
Alpha Omega Alpha
American Academy of Pediatrics
Community Pediatrician Teaching Award, 1996
General Pediatrics Teaching Award, 1996
American Society of Pediatric Hematology/Oncology
American Society of Clinical Oncology
Brigid Leventhal Merit Award for Research in Pediatric Oncology, Presented by the American Society of Clinical Oncology, 2001
Children's Oncology Group
Children's Oncology Group Neuroblastoma Developmental Therapeutics Subcommittee
Association of Clinical Research Professionals
Best Doctors in America, 2008

Research

Principal investigator for:

NANT 03-01: "A Phase I Study of Oral Irinotecan, Temozolomide, and Cefixime in Children with Recurrent/Resistant Neuroblastoma" - trial being run through the New Approaches to Neuroblastoma Therapy Consortium (NANT)
ADVL0414: "A Phase I Study of temozolomide, Oral Irinotecan, and Vincristine for Children with Refractory Solid Tumors" - a Phase I study being run through the Children's Oncology Group
"A Pilot study of temozolomide and O6-benzylguanine for treatment of high-grade glioma, using autolologous peripheral blood stem cells genetically modified for chemoprotection" - this is a gene therapy trial for patients with high-risk brain tumors to be run through Cincinnati Children's

Publications, Most Recent

Connect to Lars Wagner's publications on PubMed

Wagner LM, Villablanca JG, Stewart CF, Crews KR, O'Shaughnessy M, Groshen S, Reynolds CP, Park JR, Maris JM, Matthay KK. Phase I study of oral irinotecan, temozolomide, and cefixime in children with relapsed high-risk neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium study. Manuscript in preparation.

Wagner LM, Crews K, Stewart CF, Rodriguez-Galindo C, McNall-Knapp R, McAllister N, Pappo AS, Furman WL. Reducing irinotecan-associated diarrhea in children. Pediatr Blood & Cancer 2008; 50:201-7.

Wagner LM, Garrett JK, Hill DA, Biegel JA, Ballard ET, Collins MH. Malignant rhabdoid tumor mimicking hepatoblastoma: A case report and review of the literature. Pediatr & Develop Pathol 2007; 10: 409-15.

Wagner LM, McLendon RE, Yoon KJ, Weiss BD, Billups CA, Danks MK. Targeting methylguanine-DNA methyltransferase (MGMT) in the treatment of neuroblastoma. Clin Cancer Res 2007; 13: 5418-25.

Will E, Bailey J, Balcik B, Burzynski B, Witte D, Layh-Schmitt, von Kalle C, Baum C, Sorrentino BP, Wagner LM, Kelly P, Reeves L, Williams DA. Importance of murine study design for testing toxicity of retroviral vectors in support of Phase I trials. Mol Ther 2007; 15: 782-91.

Wagner LM, McCallister N, Goldsby RE, Rausen AR, McCarville B, Albritton K. Temozolomide and intravenous irinotecan for the treatment of advanced Ewing sarcoma. Pediatr Blood & Cancer 2007; 48: 132-7.

Presentations, Most Recent:

"Targeted therapies in early clinical trials of osteosarcoma." Advances in the Diagnosis and Management of Musculoskeletal Tumors, Cincinnati, OH, 2007.

"Does adjusting therapy based on tissue necrosis change the outcome? An overview of Children's Oncology Group Study AOST0331." Advances in the Diagnosis and Management of Musculoskeletal Tumors, Cincinnati, OH, 2007.

Abstracts, Most Recent

Balcik B, Leemhuis T, Reeves L, Murphy L, Wagner LM, Williams D. Clinical –scale transduction of a drug resistance gene into hematopoietic progenitor cells using a retroviral vector. 2007 Annual American Association of Blood Banks Annual Meeting, Anaheim, CA.

Wagner LM, Villablanca JG, Stewart CF, Crews KR, O'Shaughnessy MA, Groshen S, Reynolds CP, Park JR, Maris JM, Matthay KK. Phase I study of oral irinotecan and temozolomide in children with relapsed high-risk neuroblastoma: A New Approach to Neuroblastoma Therapy (NANT) Consortium study. 2007 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Published in Proc Am Soc Clin Oncol 2007: 542s (abstract 9567).

Perentesis JP, Wagner LM, Ames MM, Reid JM, Stewart CF, Ingle AM, Blaney AM, Adamson PC. Phase I study of oral irinotecan, temozolomide, and vincristine for children with refractory solid tumors: A Children's Oncology Group study. 2007 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Published in Proc Am Soc Clin Oncol 2007: 541s (abstract 9563).